-
Study aim
-
The Effect of Oleoylethanolamide on Glycemic Control, Serum Levels of TNF-α and miRNA126a in Patients with Type 2 Diabetes
-
Design
-
A study will involve 66 patients with type 2 diabetes, divided into two groups: one receiving 200 mg of OEA supplement and the other a placebo for 3 months. Participants will also follow a restricted-calorie diet and increased physical activity. Adherence to the interventions will be monitored through weekly contacts and pill counts.
-
Settings and conduct
-
This study will be conducted at the Research Institute of Endocrinology and Metabolism at the Tehran University of Medical Sciences. Blood samples will be collected from participants before and after the intervention to assess serum levels of TNF-α, HbA1c, and GLP-1 using ELISA, and miRNA-146-a using Real-Time PCR. Blood glucose levels will be measured with an auto-analyzer. Food intake and anthropometric indices will be measured at the beginning and end of the study as well.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: patients with type 2 diabetes, aged 18-65 years, willing to participate in the study, having body mass index (BMI) > 25 kg/m2
Exclusion criteria: Patients with any metabolic disease and a history of drug or alcohol abuse within the past 6 months
-
Intervention groups
-
Diabetes patients who receive 200 mg of OEA supplement
-
Main outcome variables
-
FPG, Insulin, HbA1c, GLP-1, TNF-α, miRNA 146a, age, sex, weight, Waist/hip circumference, Body mass index, Food intake